Patents Issued in October 2, 2007
  • Patent number: 7276505
    Abstract: Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(?O)NR6R7, —NR7C(?O)R6, —NR7C(?O)OR6, —NHC(?O)NR7R6 or —NHC(?S)NR7R6 wherein R6 represents H, or a radical of formula -(Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R8)— links wherein R8, represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H; —NR9R10 wherein R9 and R10 independently represents H; C1-C4 alkyl; C3-C4 alkenyl; C3-C4 alkynyl; C3-C6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R9
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: October 2, 2007
    Assignee: Medigene Limited
    Inventor: Ian Richard Matthews
  • Patent number: 7276506
    Abstract: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, having the formula: wherein X represents an oxygen atom or a group with the formula NZ and wherein: R1 C1-7 alkyl or arylalkyl; Z is a group independently defined as R1 or the group NZ together with R1 is an optionally substituted heterocyclic group containing at least one nitrogen atom; R2 is amino or acylamino; R4 is an atom or a group selected from the group consisting of hydrogen; C1-7 alkyl; and C1-7 alkoxy; and R3 is an atom or a group selected from the group consisting of aryl optionally substituted with one or more substituents selected from the group consisting of halogen, C1-7 alkyl, and C1-7 alkoxy, their pharmaceutically acceptable salts, and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and being useful in the treatment in transplant rejection, certain inflammatory diseases, cardiovascular disorders, allergi
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: October 2, 2007
    Assignee: 4 Aza Bioscience NV
    Inventors: Mark Jozef Albert Waer, Piet André Maurits Maria Herdewijn, Wolfgang Eugen Pfleiderer
  • Patent number: 7276507
    Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: October 2, 2007
    Assignee: AEterna Zentaris GmbH
    Inventors: Eckhard Claus, Eckhard Günther, Irene Seipelt, Ulf R. Rapp, Ludmilla Wixler
  • Patent number: 7276508
    Abstract: The present invention relates to dopamine D4 ligands having the general formula I wherein R1-R10, W, X, Y1-Y4, and n are as described herein. The compounds of the invention are potent dopamine D4 receptor ligands.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: October 2, 2007
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Jakob Felding, Jan Kehler, Kim Andersen
  • Patent number: 7276509
    Abstract: The present invention relates to piperidine derivatives of formula (I): wherein R represents halogen or C1-4 alkyl; R1 represents hydrogen or C1-4 alkyl; R2 represents hydrogen, C1-4 alkyl; R3 represents hydrogen, C1-4 alkyl; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R5 represents hydrogen, C1-4 alkyl, C3-7 cycloalkyl, C(O)R6 or S(O)2R6; R6 represents C1-4 alkyl or C3-7 cycloalkyl; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is an integer from 1 to 2; X and Y are independently C(O) or CH2; provided that i) X and Y are not both C(O) and ii) when X and Y are both CH2 and p is 1, R5 is not hydrogen, C1-4 alkyl or C(O)R6; and pharmaceutically acceptable salts and solvates thereof, the process for their preparation and their use in the treatment of conditions mediated by tachykinins.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: October 2, 2007
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, Romano Di Fabio
  • Patent number: 7276510
    Abstract: This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, provided that when Q is halo then Z is N; or when Q is polyhaloC1-6alkyl then Y is hydrogen or C1-6alkyl; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: October 2, 2007
    Assignee: Janssen Pharmaceutica, Inc.
    Inventors: Michael Joseph Kukla, Donald William Ludovici, Robert William Kavash, Bart Lieven Daniel De Corte, Jan Heeres, Paul Adriaan Jan Janssen, Lucien Maria Henricus Koymans, Marc René de Jonge, Koen Jeanne Alfons Van Aken, Alain Krief, Ruben Gerardus George Leenders
  • Patent number: 7276511
    Abstract: The invention provides a compound which exhibits satisfactory peroral absorbability and excellent antagonistic activity against NK-1 receptor or NK-2 receptor.
    Type: Grant
    Filed: August 2, 2004
    Date of Patent: October 2, 2007
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Masaaki Nagasawa, Nobuo Kawase, Nobuyuki Tanaka, Hideki Nakamura, Naoki Tsuzuike, Masakazu Murata
  • Patent number: 7276512
    Abstract: A compound selected from those of formula (I): wherein: X and Y represent a group selected from hydrogen, halogen, hydroxy, alkoxy, nitro, cyano, alkyl, trihaloalkyl and NRaRb, wherein Ra and Rb are as defined in the description R1 represents hydrogen or alkyl R2 represents a group selected from hydrogen, alkyl, —OR?a, —NR?aR?b, —O-Ta-OR?a, —NR?a-Ta-NR?aR?b, —NR?a—C(O)-TaH, —O—C(O)-TaH, —O-Ta-NR?aR?b, —NR?a-Ta-OR?a, —NR?a-Ta-CO2R?a and —NR?a—C(O)-Ta-NR?aR?b, wherein R?a, R?a, R?b and Ta are as defined in the description R3 and R4 represent hydrogen or alkyl A represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH—, —C(O)—CH(R8) or —CH(R8)—C(O), wherein R5, R6, R7 and R8 are as defined in the description its isomers, N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: October 2, 2007
    Assignee: Les Laboratoires Servier
    Inventors: Michel Koch, François Tillequin, Sylvie Michel, John Hickman, Alain Pierre, Stéphane Leonce, Bruno Pfeiffer, Pierre Renard
  • Patent number: 7276513
    Abstract: There is provided a compound of formula XII, wherein G is H or a substituent, and wherein R1 is a sulphamate group.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: October 2, 2007
    Assignee: Sterix, Ltd.
    Inventors: Barry Victor Lloyd Potter, Michael John Reed, Lok Wai Lawrence Woo
  • Patent number: 7276514
    Abstract: The invention includes composition comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a compression of the invention with a human patient.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: October 2, 2007
    Assignee: Charitable Leadership Foundation - Medical Technology Acceleration Program
    Inventor: Paul J. Davis
  • Patent number: 7276515
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: October 2, 2007
    Assignee: Coley Pharmaceutical Group, Inc.
    Inventors: Joseph F. Dellaria, Matthew R. Radmer
  • Patent number: 7276516
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
  • Patent number: 7276517
    Abstract: Heterocyclic amides of formula (1) wherein: X is N or CH; R4 and R5 together are either —S—C(R6)?C(R7)— or —C(R7)?C(R6)—S—; R6 and R7 are independently selected from, for example hydrogen, halo and C1-4alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R2 is hydrogen, hydroxy or carboxy; R3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8 groups); R8 is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R10), —NHC(O)R9, (R9)(R10)N— and —COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof, possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: October 2, 2007
    Assignee: AstraZeneca AB
    Inventors: Alan Martin Birch, Andrew David Morley, Andrew Stocker, Paul Robert Owen Whittamore
  • Patent number: 7276518
    Abstract: Substituted cyclohexane-1,4-diamine compounds, methods for production thereof, pharmaceutical compositions comprising these compounds and methods of treatment using these compounds.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: October 2, 2007
    Assignee: Gruenenthal GmbH
    Inventors: Bernd Sundermann, Hagen-Heinrich Hennies, Werner Englberger, Babette-Yvonne Koegel
  • Patent number: 7276519
    Abstract: This invention provides compounds of Formula (1a)–(1f), II wherein: X, m, n, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Q, Z, Z?, Z??, Z? and J are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, myocardial infarction, neuropathic pain, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 2, 2007
    Assignee: Wyeth
    Inventors: Diane Harris Boschelli, Nan Zhang, Ana Carolina Barrios Sosa, Haris Durutlic, Biqi Wu
  • Patent number: 7276520
    Abstract: Certain novel bicyclic N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: October 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ravi P. Nargund, Zhixiong Ye, Liangqin Guo
  • Patent number: 7276521
    Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: October 2, 2007
    Assignee: Glaxo Group Limited
    Inventors: Jakob Busch-Petersen, Michael R. Palovich, Zehong Wan, Hongxing Yan, Chongjie Zhu
  • Patent number: 7276522
    Abstract: The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: October 2, 2007
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Phong Nguyen, Daniel Gil, John E. Donello
  • Patent number: 7276523
    Abstract: Aminopyridine derivatives of the following formula I which exhibit pharmacological activity at estrogen receptors alpha (ER?) and beta (ER?) are described herein. The described invention also includes compositions and medicaments containing the aminopyridine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: October 2, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: David Harold Drewry, Brad Richard Henke
  • Patent number: 7276524
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: October 2, 2007
    Assignee: Astellas Deutschland GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 7276525
    Abstract: It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator. The present invention relates to an enhancer for an osteogenesis accelerator, which comprises a compound having a TGF-? selective inhibitory activity as an active ingredient, the enhancer being administered with an osteogenesis accelerator containing BMP as an active ingredient either simultaneously or sequentially, and to a method of screening for an enhancer for an osteogenesis accelerator, comprising using a TGF-? inhibition as a measure for discovering the enhancer.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: October 2, 2007
    Assignee: Nippon Shinyaku Co. Ltd.
    Inventors: Kohei Miyazono, Takeshi Imamura, Shingo Maeda
  • Patent number: 7276526
    Abstract: Provided herein are novel substituted thiazoles and oxazoles of the Formula (I): as well as compositions, including pharmaceutical compositions, containing the same, and the use thereof in the treatment of various neurological and psychological disorders, e.g., affective disorder, anxiety and depression, treatable by antagonizing CRF receptors.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: October 2, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Andreas Termin, Peter Grootenhuis, Dean Wilson, Valentina Molteni, Long Mao
  • Patent number: 7276527
    Abstract: An optionally N-oxidized compound represented by the formula: wherein R1 represents hydrogen, hydrocarbon, heterocycle, amino, acyl, R2 represents an aromatic group, R3 represents hydrogen, pyridyl, aromatic hydrocarbon, X represents oxygen, optionally oxidized sulfur, Y represents a bond, an oxygen, optionally oxidized sulfur, a group represented by the formula NR4 (R4 represents hydrogen, hydrocarbon or acyl) and Z represents a bond or a divalent acyclic hydrocarbon, or a salt thereof has an excellent adenosine A3 receptor antagonistic activity and is used as an agent for preventing or treating diseases related to an adenosine A3 receptor. Furthermore, the compound (I) or a salt thereof has p38 MAP kinase inhibitory activity and TNF-? inhibitory activity and is used as an agent for preventing or treating diseases related to p38 MAP kinase and diseases related to TNF-?.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: October 2, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigenori Ohkawa, Naoyuki Kanzaki, Seiji Miwatashi
  • Patent number: 7276528
    Abstract: There are provided novel compounds of formula (I) wherein A, R1, R3, R4, R5, T, U, V, W, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory diseases, pain and CNS diseases.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: October 2, 2007
    Assignee: AstraZeneca AB
    Inventors: Stephen Connolly, Glen Ernst
  • Patent number: 7276529
    Abstract: Methods of treating, managing or preventing exercise-induced asthma are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: October 2, 2007
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Peter H. Schafer, Patricia E. W. Rohane
  • Patent number: 7276530
    Abstract: Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial infections with the disclosed compounds or the disclosed pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: October 2, 2007
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Barbara Christine Potts, Venkat Macherla, Scott Sherman Mitchell, Ram Rao Manam, Katherine Reed, Kin Sing Lam, Saskia Neuteboom, Ta-Hsiang Chao, Benjamin Nicholson, Cheryl Billstrom
  • Patent number: 7276531
    Abstract: A gamma-lactam diene of Formula I: which is particularly useful as a medicament for the treatment of various disorders such as asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: October 2, 2007
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gian Luca Araldi, Srinivasa Karra, Zhong Zhao, Nadia Brugger
  • Patent number: 7276532
    Abstract: The present invention provides a therapeutic agent for overactive bladder comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X1—X2—X3 represents CR5?CR6—CR7?CR8, CR5?CR6—S, and the like; Y represents —CH2S—, —SOCH2—, and the like; and R2 represents a hydrogen atom, and the like] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 2, 2007
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Tsuyoshi Yamagata, Kaoru Atsuki, Tetsuji Ohno, Shiro Shirakura, Akira Karasawa
  • Patent number: 7276533
    Abstract: This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPAR? receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPAR? receptor, such as the acute malignant haemopathies.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Pisano, Teresa Riccioni
  • Patent number: 7276534
    Abstract: Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: October 2, 2007
    Assignee: Emisphere Technologies, Inc.
    Inventor: Sam J. Milstein
  • Patent number: 7276535
    Abstract: A low effective dose of a biologically acceptable chemical sterilant is injected into the dorsal cranial portion of a scrotal testis of a male animal for the purpose effecting sterilization of the animal. The injection of the chemical sterilant into the dorsal cranial portion has an effect on the epithelium of the tubuli recti, rete testis and ductus efferentes in addition to stopping spermatogenesis in the seminiferous tubules.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: October 2, 2007
    Assignee: Technology Transfer, Inc.
    Inventor: Min Wang
  • Patent number: 7276536
    Abstract: The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug with food to improve bioavailability.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: October 2, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Yasuo Urata, Tomohiro Ishikawa
  • Patent number: 7276537
    Abstract: A compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R?R? of at least 2 carbon atoms and R? and R? are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 dihydroxyalkyl groups, or R? and R? together are a C2-6 alkylene group, is formulated so that upon dissolution in aqueous solution the pH of the solution is in the range of 5 to 9. The compound may be in the form of salt with a physiologically acceptable acid having a pKa in the range of ?3.0 (minus 3.0) to 9.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: October 2, 2007
    Assignee: BTG International Limited
    Inventors: William Alexander Denny, Laurence Hylton Patterson, Gavin William Halbert, Steven John Ford
  • Patent number: 7276538
    Abstract: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl) tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: October 2, 2007
    Assignee: Giuliani S.p.A.
    Inventors: Fabio Rinaldi, Elisabetta Sorbellini, Valter Gatti, Danila Ingrid Marchioretto
  • Patent number: 7276539
    Abstract: A compound of formula I wherein R1 represents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: October 2, 2007
    Assignee: AstraZeneca AB
    Inventors: Eva-Lotte Alstermark Lindstedt, Anna Maria Persdotter Boije, Patrick Holm
  • Patent number: 7276540
    Abstract: The present invention relates to thermally stable, high surface area alumina supports and a method of preparing such supports with at least one modifying agent. The method includes adding an aluminum modifying agent to the alumina prior to calcining. The inventive support has thermal stability at temperatures above 800° C. A more specific embodiment of the invention is a catalyst having a high surface area, thermally stable alumina support with at least one group VIII metal or rhenium and an optional promoter loaded onto the support. The present invention further relates to gas-to-liquids conversion processes, more specifically for producing C5+ hydrocarbons.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: October 2, 2007
    Assignee: ConocoPhillips Company
    Inventors: Rafael L. Espinoza, Dan Fraenkel, Kevin L. Coy
  • Patent number: 7276541
    Abstract: The invention provides for the use of hydroxyl-functional polyalkylorganosiloxanes of the general formula (IV) as solvents for cationic photoinitiators and for the use of these solutions in cationically curable silicones.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: October 2, 2007
    Assignee: Goldschmidt AG
    Inventors: Hardi Döhler, Sascha Oestreich
  • Patent number: 7276542
    Abstract: An ultraviolet (UV) light curable formulation useful for repairing composite materials, comprising: an acrylic oligomer, an acrylic monomer, and a photoinitiator. This formulation may include fiberglass. The photoinitiator can be a combination of a bis-acylphosphine oxide and an alpha hydroxy ketone. The formulation can cure rapidly, such as in about 20 minutes. The cured formulation can have a Tg above 150° C.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: October 2, 2007
    Assignee: Texas Research International, Inc.
    Inventors: John W. Bulluck, Brad A. Rix
  • Patent number: 7276543
    Abstract: The present invention relates to a coated optical fiber comprising a glass optical fiber with a single protective coating or a combination of an inner and an outer primary coating applied thereon and optionally with a colored coating subsequently applied thereon wherein the inner primary coating or at least a portion of the single coating is prepared from a radiation curable composition which when cured as a capillary film with a 100W medium pressure mercury lamp has a percentage reacted acrylate unsaturation of at least about 54% after exposure to a dose of about 4.4 mJ/cm2 or wherein the outer primary coating is prepared from a radiation curable composition which when cured as a capillary film with a 100 W medium pressure mercury lamp has a percentage reacted acrylate unsaturation of at least about 56% after exposure to a dose of about 4.4 mJ/cm2. The invention further relates to a radiation curable composition having a high cure speed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 2, 2007
    Assignee: DSM IP Assets B.V.
    Inventors: Timothy E. Bishop, Paul E. Snowwhite, Tyson Norlin, James J. Schouten, John Southwell, Anthony Toussaint
  • Patent number: 7276544
    Abstract: A process for producing intraocular lenses (IOLs) capable of absorbing blue light and ultraviolet light using photo curing. Intraocular lenses so produced block blue light and ultraviolet light from reaching the retina of an eye implanted with the IOL. By blocking blue light and ultraviolet light from reaching the retina, the IOL thereby prevents potential damage to the retina.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: October 2, 2007
    Assignee: Bausch & Lomb Incorporated
    Inventors: Yu-Chin Lai, Dominic V. Ruscio, George F. Green
  • Patent number: 7276545
    Abstract: Mixtures of chain-extended N-alkylaziridino prepolymers are disclosed herein. The disclosed mixtures of chain-extended N-alkylaziridino prepolymers can be used in combination with additional materials to make curable formulations that can be used, for example, as dental materials such as impression compounds.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: October 2, 2007
    Assignee: 3M ESPE AG
    Inventors: Gunther Eckhardt, Guenther Lechner, Erich Wanek
  • Patent number: 7276546
    Abstract: The invention relates to methods of making carbohydrate and polyol esters suitable for use as plasticizers for polymer compositions. The invention also relates to plasticized polymer compositions comprising such carbohydrate and polyol esters. The invention also relates to articles prepared from such plasticized polymer compositions. The invention further relates to methods of using these compositions.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: October 2, 2007
    Assignee: Eastman Chemical Company
    Inventors: Charles M. Buchanan, Norma L. Buchanan, Kevin J. Edgar, Juanelle L. Lambert
  • Patent number: 7276547
    Abstract: Compositions comprising at least one structuring polymer and at least one oil-soluble polymer chosen from alkyl celluloses and alkylated guar gums. The compositions may further comprise at least one fatty alcohol. This composition may be in the form of stable compositions such as, for example, make-up sticks, lipsticks and sunscreen sticks.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: October 2, 2007
    Assignee: L'Oreal S.A.
    Inventors: Carlos Pinzon, Paul Thau
  • Patent number: 7276548
    Abstract: The present invention provides a colorant-containing curable composition comprising a colorant, wherein the colorant contains a compound represented by the following Formula (I). In Formula (I), R1 and R2 each independently represent H, an alkyl group, an alkenyl group, an aryl group, or an aralkyl group. R1 and R2 may be formed into a heterocycle together with a jointly bonded nitrogen atom. R3 represents a halogen atom, a trihalomethyl group, an alkoxy group, a nitro group, or an amino group. n represents an integer of 0 to 4. R4 represents a halogen atom or a —SO3M group, in which M represents H, a cation of a metallic atom, or a cation consisting of a nitrogen-containing compound. m represents an integer of 0 to 5. The present invention further provides a color filter comprising the compound represented by Formula (I) and a method for manufacturing the color filter.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: October 2, 2007
    Assignee: Fujifilm Corporation
    Inventor: Katsumi Araki
  • Patent number: 7276549
    Abstract: A coating for preparing a floor underlayment to receive an adhesive includes a water-soluble, latex polymer, a defoamer and a dual-function surface enhancing agent. The surface enhancing agent includes a set accelerator that also functions to cross link the adhesive, hardening the surface of the underlayment using at least two mechanisms. One embodiment of the invention is a dry mixture that forms a coating when added to water. The dry mixture includes from about 10% to about 50% of the redispersible polymer by weight based on the mixture, from about 50% to about 90% of the surface enhancing agent and from about 0.15% to about 0.25% of the defoamer by weight based on the mixture. Other embodiments describe a liquid coating formed by adding from about 1 to about 8 pails water to 1 part of the dry mixture on a volumc basisby volume based on the mixture.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: October 2, 2007
    Assignee: United States Gypsum Company
    Inventors: Qingxia Liu, John W. Ellicson, David McDonald
  • Patent number: 7276550
    Abstract: This invention is based upon the discovery that elongated silica has superior characteristics for reinforcing rubbery elastomers as compared to conventional silica. More specifically, elongated silica provides a higher level of reinforcement for elastomers at the same level of loading. Accordingly, elongated silica can be employed to attain an equivalent level of reinforcement at a lower level of loading. This results in lower weight compositions and potential cost savings. Rubber compounds that are reinforced with elongated silica offer significant advantages in tires including reduced rolling resistance, increased tread life, and, of course, reduced weight. The subject invention more specifically relates to a silica reinforced rubber composition which is comprised of (1) a rubbery polymer and (2) an elongated silica, wherein the elongated silica has a width that is within the range of about 5 nm to about 40 nm and wherein the elongated silica has a length of about 40 nm to about 300 nm.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: October 2, 2007
    Assignee: The Goodyear Tire & Rubber Company
    Inventors: Howard Allen Colvin, Sun Lin Chen
  • Patent number: 7276551
    Abstract: The present invention relates to a novel cement composition. This cement may be combined with a number of different products, including residual materials such as polystyrene, glass, cork, fiberglass, cellulose fibers, wood fibers and wood shavings, as well as with minerals or compositions such as zonolite or vermiculite. The resultant concrete exhibits physical and chemical characteristics that make it suitable for use in construction projects, including resistance to freeze-thaw cycles.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: October 2, 2007
    Inventor: Jean-Roch Pageau
  • Patent number: 7276552
    Abstract: The use of NIPAM polymers to prevent or reduce the formation of protein deposits on the surfaces of medical devices is described. The invention is particularly directed to reduction of the adsorption of proteins on surfaces of contact lenses and other medical prosthetics.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 2, 2007
    Assignee: Alcon, Inc.
    Inventor: Howard Allen Ketelson
  • Patent number: 7276553
    Abstract: A stable, chromatic water-in-silicone emulsion comprising: i) an aqueous phase containing a water-soluble polyol, a water-soluble polymer thickener, and water; and ii) a silicone phase containing an aromatic silicone, a silicone emulsifier and a silicone fluid carrier.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: October 2, 2007
    Assignee: Avon Products, Inc.
    Inventors: Mark S. Garrison, Walter J. Carmody
  • Patent number: 7276554
    Abstract: Coating compositions that are stable to thermal yellowing that include coating materials containing I) one or more dispersions of hydroxyl-free polyurethanes and/or polyurethane-ureas, II) one or more aqueous solutions or dispersions of ionically modified, hydroxyl-containing polyurethanes and/or polyurethane-ureas, other than the constituents of component I), and III) at least one crosslinker.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: October 2, 2007
    Assignee: Bayer MaterialScience AG
    Inventors: Thorsten Rische, Torsten Pohl, Jürgen Meixner, Uwe Klippert, Thomas Feller